{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:21:44Z","timestamp":1787847704751,"version":"build-2784847793"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve kidney and cardiovascular outcomes in type 2 diabetes, chronic kidney disease, and heart failure, but optimal initiation timing after dialysis-requiring acute kidney injury (AKI-D) is uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare outcomes associated with SGLT-2 inhibitor prescription within 30 days vs 31 to 90 days after discharge among adults with type 2 diabetes recovering from AKI-D.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study using a target trial emulation design used TriNetX Global Collaborative Network electronic health records from January 1, 2015, to September 1, 2024. Eligible adults had type 2 diabetes, were hospitalized for AKI-D, had dialysis discontinued after discharge, and had no SGLT-2 inhibitor prescription in the prior year.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n First documented SGLT-2 inhibitor prescription within 30 days after discharge vs 31 to 90 days after discharge.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Primary outcomes were adverse kidney events, all-cause mortality, and major adverse cardiovascular events. Adverse kidney events included dialysis reinitiation, incident end-stage kidney disease, or recorded estimated glomerular filtration rate less than 15 mL\/min\/1.73 m\n 2<\/jats:sup>\n . Selected 6-month safety outcomes were also assessed. A 90-day landmark design and 1:1 propensity score matching were used.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 4406 eligible patients before propensity score matching, 2268 initiated SGLT-2 inhibitors within 30 days (mean [SD] age, 63.5 [12.9] years; 1336 male [58.9%]), and 2138 initiated SGLT-2 inhibitors between 31 and 90 days (mean [SD] age, 62.7 [13.5] years; 1210 male [56.6%]). After 1:1 propensity score matching, 1912 patients remained in each group (mean [SD] age, 63.0 [13.0] vs 62.8 [13.5] years; 1102 [57.6%] vs 1112 [58.2%] male, in the early vs late SGLT-2 initiation groups, respectively). During a mean follow-up of 3.4 years (IQR, 1.1-3.3 years), early prescription was associated with a lower risk of adverse kidney events compared with late prescription in 74 patients (3.9%) vs 119 patients (6.2%) (adjusted hazard ratio [AHR], 0.62; 95% CI, 0.46-0.83). All-cause mortality (AHR, 1.06; 95% CI, 0.84-1.35;\n P<\/jats:italic>\n \u2009=\u2009.63) and major adverse cardiovascular events (AHR, 1.03; 95% CI, 0.80-1.34;\n P<\/jats:italic>\n \u2009=\u2009.81) did not differ significantly. Recorded 6-month safety outcomes were also similar.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In adults with type 2 diabetes recovering from AKI-D, SGLT-2 inhibitor prescription within 30 days after discharge was associated with fewer adverse kidney events than prescription at 31 to 90 days, without significant differences in mortality, cardiovascular events, or recorded short-term safety outcomes. These findings support timely initiation of SGLT-2 inhibitors during the post-AKI recovery period and provide a rationale for prospective randomized clinical trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.31231","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:30:29Z","timestamp":1787844629000},"page":"e2631231","source":"Crossref","is-referenced-by-count":0,"title":["Early Sodium-Glucose Cotransporter-2 Inhibitor Use After Acute Kidney Injury in Type 2 Diabetes"],"prefix":"10.1001","volume":"9","author":[{"given":"Yu-Ting","family":"Chou","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan"},{"name":"Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Hong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Primary Aldosteronism Center of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"National Taiwan University Hospital Study Group of Acute Renal Failure and Taiwan Consortium for Acute Kidney Injury and Renal Diseases, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"8","key":"zoi260855r1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation.","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"zoi260855r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101760","article-title":"Outcomes associated with acute kidney disease: a systematic review and meta-analysis.","volume":"55","author":"Su","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"4","key":"zoi260855r3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup.","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"24","key":"zoi260855r4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi260855r5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260855r6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12933-023-02035-8","article-title":"Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.","volume":"22","author":"Chen","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"zoi260855r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease.","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi260855r8","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations.","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"8","key":"zoi260855r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2025.103081","article-title":"Early prescription of SGLT2i for acute patient care: from current evidence to future directions.","volume":"50","author":"Ricci","year":"2025","journal-title":"Curr Probl Cardiol"},{"issue":"6","key":"zoi260855r10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.14740\/jocmr3011w","article-title":"Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors.","volume":"9","author":"Sano","year":"2017","journal-title":"J Clin Med Res"},{"issue":"11","key":"zoi260855r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277321","article-title":"Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: propensity score matched analysis.","volume":"17","author":"Sun","year":"2022","journal-title":"PLoS One"},{"issue":"24","key":"zoi260855r12","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"20","key":"zoi260855r13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"zoi260855r14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/pds.5482","article-title":"Core concepts in pharmacoepidemiology: fundamentals of the cohort and case-control study designs.","volume":"31","author":"Potteg\u00e5rd","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi260855r15","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"zoi260855r16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study.","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"zoi260855r17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4088\/JCP.20f13681","article-title":"Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets.","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"zoi260855r18","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values.","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"535","key":"zoi260855r19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1080\/01621459.2020.1745813","article-title":"Bayesian factor analysis for inference on interactions.","volume":"116","author":"Ferrari","year":"2021","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"zoi260855r20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure.","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"zoi260855r21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ejhf.3464","article-title":"Timing of sodium-glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: a population-based cohort study.","volume":"27","author":"Wu","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"zoi260855r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT Registry.","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"issue":"1","key":"zoi260855r23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-025-02592-0","article-title":"Association of sodium-glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis.","volume":"24","author":"Maremmani","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"zoi260855r24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"zoi260855r25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors.","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"13","key":"zoi260855r26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms25137057","article-title":"The renoprotective mechanisms of sodium-glucose cotransporter-2 inhibitors (SGLT2i)-a narrative review.","volume":"25","author":"Iordan","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"zoi260855r27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback.","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"issue":"6","key":"zoi260855r28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.xkme.2021.06.012","article-title":"Kidney recovery in patients with acute kidney injury treated in outpatient hemodialysis or rehabilitation facilities.","volume":"3","author":"Jordan","year":"2021","journal-title":"Kidney Med"},{"issue":"1","key":"zoi260855r29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"zoi260855r30","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis.","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"zoi260855r31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"zoi260855r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112339","article-title":"Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy.","volume":"226","author":"Chen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"zoi260855r33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4093\/dmj.2023.0201","article-title":"Abrupt decline in estimated glomerular filtration rate after initiating sodium-glucose cotransporter 2 inhibitors predicts clinical outcomes: a systematic review and meta-analysis.","volume":"48","author":"Chuang","year":"2024","journal-title":"Diabetes Metab J"},{"issue":"5","key":"zoi260855r34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials.","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi260855r35","doi-asserted-by":"publisher","DOI":"10.1177\/1073274818789355","article-title":"Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the National Cancer Database.","author":"Agarwal","year":"2018","journal-title":"Cancer Control"},{"issue":"2","key":"zoi260855r36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer.","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853354\/chou_2026_oi_260855_1787237416.99804.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:30:30Z","timestamp":1787844630000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.31231","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}